Kidney Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 155 Published: May 31, 2022 Report Code: GDGMDHC22195IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection – Drugs In Development, 2022, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 10, 7, 21, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.

Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).

– The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Alphamab Oncology

AltruBio Inc

Amgen Inc

Amyndas Pharmaceuticals LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Cynata Therapeutics Ltd

Eledon Pharmaceuticals Inc

Enceladus Pharmaceuticals BV

Hansa Biopharma AB

Helocyte Biosciences Inc

Hillhurst Biopharmaceuticals Inc

Horizon Therapeutics Plc

Idogen AB

ITB-Med AB

JN Biosciences LLC

Junten Bio Co Ltd

Kiniksa Pharmaceuticals Ltd

Kronos Bio Inc

Lignamed LLC

Lyndra Therapeutics Inc.

Medeor Therapeutics Inc

MyeloRx LLC

Nekonal Sarl

NextCell Pharma AB

OSE Immunotherapeutics

Paranta Biosciences Ltd

Pharmapraxis

Rigel Pharmaceuticals Inc

Sangamo Therapeutics Inc

Sanofi

Suzhou Regend Therapeutics Co Ltd

SYnAbs SA

Talaris Therapeutics Inc

TolerogenixX GmbH

Tonix Pharmaceuticals Holding Corp

Xenothera SAS

Zenas BioPharma (USA) LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Kidney Transplant Rejection – Overview

Kidney Transplant Rejection – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Kidney Transplant Rejection – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kidney Transplant Rejection – Companies Involved in Therapeutics Development

Kidney Transplant Rejection – Drug Profiles

Kidney Transplant Rejection – Dormant Projects

Kidney Transplant Rejection – Discontinued Products

Kidney Transplant Rejection – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Kidney Transplant Rejection, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Kidney Transplant Rejection – Dormant Projects, 2022

Kidney Transplant Rejection – Dormant Projects, 2022 (Contd..1)

Kidney Transplant Rejection – Dormant Projects, 2022 (Contd..2)

Kidney Transplant Rejection – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Kidney Transplant Rejection, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.